Zosuquidar (LY335979) 3HCl: A Selective P-gp Inhibitor for Multidrug Resistance Reversal

Executive Summary: Zosuquidar (LY335979) 3HCl is a third-generation, selective P-glycoprotein (P-gp) inhibitor developed to reverse multidrug resistance (MDR) in cancer models. It competitively blocks the efflux function of P-gp, restoring intracellular chemotherapeutic drug concentrations and sensitizing resistant tumor cells (https://www.apexbt.com/zosuquidar.html). Clinical and preclinical studies report effective reversal of MDR at low micromolar concentrations without altering drug pharmacokinetics (https://doi.org/10.1016/j.biopha.2025.118665). Zosuquidar demonstrates efficacy across leukemia and solid tumor models, supporting its value in combination chemotherapy regimens. Its use is well tolerated with minimal toxicity in early-phase human trials.

Biological Rationale

P-glycoprotein (P-gp, ABCB1) is an ATP-dependent efflux pump highly expressed in tissues such as the brain, liver, small intestine, and especially in various tumor cells. P-gp actively exports xenobiotics and chemotherapeutic agents out of cells, decreasing their intracellular concentrations and leading to multidrug resistance (MDR) in cancer therapy (DOI:10.1016/j.biopha.2025.118665). This resistance impairs treatment efficacy, particularly for agents like vinblastine, doxorubicin, etoposide, and paclitaxel. Overexpression of P-gp is a major mechanism underlying MDR in acute myeloid leukemia (AML), non-Hodgkin's lymphoma, and various solid tumors. Targeting P-gp with specific inhibitors is a validated strategy for overcoming MDR and enhancing chemotherapeutic response (ref).

Mechanism of Action of Zosuquidar (LY335979) 3HCl

Zosuquidar (LY335979) 3HCl binds selectively and competitively to the drug-binding pocket of P-gp, inhibiting its ATP-dependent efflux activity. This blockade prevents the export of cytotoxic chemotherapeutic agents from tumor cells, thereby increasing intracellular drug accumulation and cytotoxicity. The compound is active at low micromolar concentrations, efficiently restoring drug sensitivity in P-gp overexpressing models. Zosuquidar does not alter the pharmacokinetics of co-administered chemotherapeutics, which distinguishes it from earlier, less selective P-gp inhibitors (DOI:10.1016/j.biopha.2025.118665; APExBIO).

Evidence & Benchmarks

• In vitro, Zosuquidar at 0.5–1 μM restores sensitivity to vinblastine, doxorubicin, etoposide, and paclitaxel in P-gp overexpressing leukemia and tumor cell lines (DOI:10.1016/j.biopha.2025.118665).
• In vivo, co-administration with chemotherapeutics enhances antitumor activity and prolongs survival in murine models of MDR leukemia and non-small cell lung carcinoma xenografts (DOI:10.1016/j.biopha.2025.118665).
• Zosuquidar does not significantly alter the pharmacokinetics (AUC, Tmax, Cmax) of partner drugs, reducing risk of adverse interactions (DOI:10.1016/j.biopha.2025.118665).
• Phase I/II clinical studies report effective P-gp inhibition and MDR reversal with minimal toxicity when combined with CHOP or vinorelbine regimens in non-Hodgkin’s lymphoma and advanced solid tumors (APExBIO).

This article extends findings in "Optimizing Chemotherapy Assays with Zosuquidar (LY335979)..." by providing detailed evidence benchmarks and clinical context beyond workflow optimization.

For protocol-specific guidance and troubleshooting, see "Solving Multidrug Resistance: Zosuquidar (LY335979) 3HCl ...", which this review supplements with broader pharmacologic and clinical data.

Applications, Limits & Misconceptions

Zosuquidar (LY335979) 3HCl is primarily deployed to reverse MDR in cancer research and clinical studies. It is effective for sensitizing P-gp overexpressing leukemia, lymphoma, and certain solid tumor cell lines to cytotoxic agents.

Common Pitfalls or Misconceptions

• Not effective against non-P-gp MDR: Zosuquidar is selective for P-gp and does not inhibit other efflux pumps such as MRP1 or BCRP.
• No intrinsic cytotoxicity: Zosuquidar does not kill cancer cells directly; its action is limited to modulating drug efflux.
• Variable efficacy in non-human models: P-gp substrate specificity can differ between species, affecting translation from murine models to human clinical scenarios.
• Stability constraints: Solutions are unstable long-term; fresh preparation in DMSO is recommended, and storage should be at -20°C (APExBIO).
• Not suitable for all MDR cancers: MDR can be multifactorial; success depends on P-gp being the dominant resistance mechanism.

This review clarifies the precise selectivity and pharmacologic boundaries of Zosuquidar, building on practical insights from "Zosuquidar (LY335979) 3HCl: Selective P-gp Inhibitor for ...".

Workflow Integration & Parameters

Zosuquidar (LY335979) 3HCl (SKU A3956, by APExBIO) is supplied as a DMSO-soluble powder, recommended for storage at -20°C. Standard working concentrations in cell-based assays range from 0.1–2 μM, with 0.5 μM being typical for reversal of MDR in vitro. For animal studies, dosing regimens should be adjusted based on species and route of administration, referencing published murine protocols. Long-term solution storage is discouraged due to stability concerns. The reagent is compatible with common chemotherapeutics and does not require co-formulation changes. For optimized protocols and troubleshooting, refer to the A3956 kit documentation and product page.

Conclusion & Outlook

Zosuquidar (LY335979) 3HCl represents a benchmark tool for reversing P-gp-mediated multidrug resistance in cancer research and early-phase clinical trials. Its high selectivity, lack of significant pharmacokinetic interactions, and established safety profile support continued evaluation in combination chemotherapy regimens. Future research will define its role in personalized MDR reversal and potential applications in non-oncologic diseases with P-gp involvement.